Chronic Venous Insufficiency Pipeline: Therapeutic Assessment, Emerging Drugs, Novel Devices, Key Pharma Players, Clinical Trials, and Growth Prospects Analysis | DelveInsight
Chronic Venous Insufficiency typically refers to lower extremity edema, skin trophic changes, and discomfort secondary to venous hypertension. Pharmaceutical companies developing therapies to treat CVI are: Verigraft AB, SerenaGroup, Alfasigma. Companies involved in the development of medical devices to treat CVI are Venarum Medical, InnoVein, Venari Medical, Hancock Jaffe Laboratories, and others.
Las Vegas, USA, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Chronic Venous Insufficiency Pipeline: Therapeutic Assessment, Emerging Drugs, Novel Devices, Key Pharma Players, Clinical Trials, and Growth Prospects Analysis | DelveInsight
Chronic Venous Insufficiency typically refers to lower extremity edema, skin trophic changes, and discomfort secondary to venous hypertension. Pharmaceutical companies developing therapies to treat CVI are: Verigraft AB, SerenaGroup, Alfasigma. Companies involved in the development of medical devices to treat CVI are Venarum Medical, InnoVein, Venari Medical, Hancock Jaffe Laboratories, and others.
DelveInsight’s ‘Chronic Venous Insufficiency Pipelne Insight 2021’ report offers detailed coverage of available, marketed, and pipeline therapies in different phases of clinical development, key companies working to advance the pipeline space, and future growth potential of the Chronic Venous Insufficiency pipeline domain.
Some of the major pointers from the Chronic Venous Insufficiency Pipeline report:
- DelveInsight’s Chronic Venous Insufficiency Pipeline analysis depicts that 3+ active players are developing 3+ pipeline therapies whereas 4+ active players are developing 4+ medical devices for Chronic Venous Insufficiency.
- Major pharmaceutical companies are developing potential drug candidates to improve the Chronic Venous Insufficiency treatment scenario, such as Verigraft AB, SerenaGroup, Alfasigma, and others.
- Few companies are involved in producing Chronic Venous Insufficiency medical pipeline devices like Venarum Medical, InnoVein, Venari Medical, Hancock Jaffe Laboratories, and others.
- Key Chronic Venous Insufficiency pipeline drug candidates/therapies such as P-TEV, TR 987, Sulodexide, and others are under investigation in different phases of clinical trials.
- Several innovative Chronic Venous Insufficiency medical pipeline devices like EVVS: EndoVenous Valve System, InnoVein Valve Treatment, BioVena, VenoValve, and others are under development.
- In August 2021, Hancock Jaffe Laboratories announced that the US Food and Drug Administration (FDA) had granted Breakthrough Device designation status to the VenoValve, the company’s lead product, which is currently set to begin its US pivotal trial.
Request for a Sample to know which pharma company is forecasted to take charge of Chronic Venous Insufficiency pipeline in the coming years @ Chronic Venous Insufficiency Emerging Therapies
The Chronic Venous Insufficiency pipeline report lays down detailed profiles of the pipeline assets, inactive and dormant assets, comparative analysis of clinical and non-clinical stage Chronic Venous Insufficiency products, comprehensive assessment of driving and restraining factors, along with the opportunities and risks in the Chronic Venous Insufficiency pipeline landscape.
Chronic Venous Insufficiency Overview
Chronic Venous Insufficiency typically refers to lower extremity edema, skin trophic changes, and discomfort secondary to venous hypertension. CVI pathophysiology is either due to reflux (backward flow) or obstruction of venous blood flow.
The most common symptoms associated with Chronic Venous Insufficiency include a tight feeling in calves or itchy, painful legs, swelling in legs or ankles, painful leg cramps or muscle spasms, varicose veins, and leg ulcers.
Treatment of Chronic Venous Insufficiency mainly aims to control the retrograde flow of blood, venous pooling, and the complications associated with these pathophysiologic processes.
Discover more about the therapeutic scenario in Chronic Venous Insufficiency @ Chronic Venous Insufficiency Ongoing Clinical Trials
Chronic Venous Insufficiency Pipeline Drugs
| Drug | Company | Phase | MoA | RoA |
| P-TEV | Verigraft AB | Phase I | Vein replacement | NA |
| TR 987 | SerenaGroup | Phase II | Dectin 1 stimulants; Macrophage stimulants; Toll-like receptor 2 modulators |
Topical |
| Sulodexide | Alfasigma | Phase III | Glycosaminoglycan stimulants | Oral |
Chronic Venous Insufficiency Pipeline Medical Devices
| Medical Devices | Company |
| EVVS: EndoVenous Valve System | Venarum Medical |
| InnoVein Valve Treatment | InnoVein |
| BioVena | Venari Medical |
| VenoValve | Hancock Jaffe Laboratories |
Learn more about major pipeline therapies in Chronic Venous Insufficiency domain @ Chronic Venous Insufficiency Pipeline Analysis
Chronic Venous Insufficiency Therapeutics Assessment
The Chronic Venous Insufficiency Pipeline report proffers an integral view of the Chronic Venous Insufficiency emerging novel therapies segmented by Stage, Product Type, Route of Administration, Molecule Type, and Mechanism of Action.
By Product Type
- Mono
- Combination
By Stage
- Discovery
- Pre-clinical
- Phase I
- Phase II
- Phase III
- Pre-registration
By Route of Administration
- Subcutaneous
- Intravenous
- Oral
- Inhalation
- Topical
By Molecule Type
- Gene therapy
- Stem cell therapy
- Small molecules
By Mechanism of Action
- Glycosaminoglycan stimulants
- Dectin 1 stimulants
- Toll-like receptor 2 modulators
Scope of the Chronic Venous Insufficiency Pipeline Report
- Coverage: Global
- Major Players: Verigraft AB, SerenaGroup, Alfasigma, Venarum Medical, InnoVein, Venari Medical, Hancock Jaffe Laboratories.
- Key Chronic Venous Insufficiency Pipeline Therapies: P-TEV, TR 987, Sulodexide
- Key Chronic Venous Insufficiency Medical Pipeline Devices: EndoVenous Valve System, InnoVein Valve Treatment, BioVena, VenoValve
For rich insights into therapeutic assessment and emerging pipeline drugs, visit @ Chronic Venous Insufficiency Pipeline Novel Therapies
Table of Contents
| 1 | Introduction |
| 2 | Executive Summary |
| 3 | Chronic Venous Insufficiency: Overview |
| 4 | Pipeline Therapeutics |
| 5 | Late Stage Products (Pre-registration) |
| 6 | Late Stage Products (Phase III) |
| 6.1 | Sulodexide: Alfasigma |
| 7 | Mid Stage Products (Phase II) |
| 7.1 | TR 987: SerenaGroup |
| 8 | Early Stage Products (Phase I) |
| 8.1 | P-TEV: Verigraft AB |
| 9 | Pre-clinical and Discovery Stage Products |
| 10 | Pipeline Medical devices: Company Profiles |
| 11 | Therapeutic Assessment |
| 12 | Medical Device Assessment |
| 13 | Inactive Products |
| 14 | Chronic Venous Insufficiency- Market Drivers and Barriers |
| 15 | Chronic Venous Insufficiency- Unmet Needs |
| 16 | Appendix |
| 17 | About DelveInsight |
Discover more about offerings of Chronic Venous Insufficiency report @ Chronic Venous Pipeline Landscape
Related Reports
DelveInsight’s ‘Atopic Dermatitis (AD) - Market Insights, Epidemiology and Market Forecast– 2030’ report delivers an in-depth understanding of the Atopic Dermatitis (AD), historical and forecasted epidemiology, market drivers, market barriers and key companies involved like Sanofi, Regeneron Pharmaceuticals, Pfizer, Japan Tobacco and Torii Pharmaceutical, Eli Lilly and Company, AbbVie, LEO Pharma, Incyte Corporation, Arena Pharmaceuticals, Oneness Biotech, Galderma, and many more.
DelveInsight’s “Chronic Hand Eczema - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Chronic Hand Eczema pipeline landscape covering pipeline drug profiles, clinical and non-clinical stage products, treatments, key companies including LEO Pharma, Asana BioSciences, Arcutis, and many others.
DelveInsight’s ‘Burns-Market Insights, Epidemiology, and Market Forecast–2030’ report deliver an in-depth understanding of the Burns historical and forecasted epidemiology, market drivers, market barriers, SWOT analysis, and key companies involved like Mallinckrodt Pharmaceuticals, Avita Medical, Vericel Corporation, KeraNetics, Integra Life Sciences Corporation, PolyNovo, Medline Industries/Anika Therapeutics, Inc, Amryt Pharma, Skingenix, RenovaCare, and others.
DelveInsight's "Chronic Wounds Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of Chronic Wounds, historical and forecasted epidemiology, market drivers, market barriers and key companies involved like ViroMed BioPharma, Novalead Pharma, Oneness Biotech, MediWound, Tissue Tech/Amniox Medical, Energenesis Biomedical, and others.
DelveInsight’s ‘Epidermolysis Bullosa (EB)-Market Insights, Epidemiology, and Market Forecast–2030’ report deliver an in-depth understanding of the EB, historical and forecasted epidemiology, market drivers, market barriers, and key companies involved like Amryt Pharma, Abeona Therapeutics, Castle Creek Pharmaceuticals, RegeneRx, Krystal Biotech, Fibrocell Technologies/Castle Creek Pharmaceuticals, RHEACELL GmbH, Holostem Terapie Avanzate, StemRim/Shionogi, and others.
Browse Through Our Blog Posts
- Key Pharma Companies Expanding their Arm in the Skin Cancer Segment
- Cervical Cancer Market Has A Lot Going On Under The Hood
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
For more insights, visit Pharma, Healthcare, and Biotech News
Contact Us Shruti Thakur info@delveinsight.com +1(919)321-6187 www.delveinsight.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
